Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

PCOS: A Chronic Disease that Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs)

Version 1 : Received: 23 August 2021 / Approved: 24 August 2021 / Online: 24 August 2021 (14:07:27 CEST)

How to cite: Regidor, P.; de la Rosa, X.; Mueller, A.; Sailer, M.; Gonzalez Santos, F.; Gracia Banzo, R.; Rizo, J.M. PCOS: A Chronic Disease that Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs). Preprints 2021, 2021080473 (doi: 10.20944/preprints202108.0473.v1). Regidor, P.; de la Rosa, X.; Mueller, A.; Sailer, M.; Gonzalez Santos, F.; Gracia Banzo, R.; Rizo, J.M. PCOS: A Chronic Disease that Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs). Preprints 2021, 2021080473 (doi: 10.20944/preprints202108.0473.v1).

Abstract

Introduction: Polycystic Ovary Syndrome (PCOS) is an endocrinologic disorder that affects 5-15 % of women of their reproductive age and is a frequent cause of infertility. Major symptoms include hyperandrogenism, ovulatory dysfunction, a characteristic multi-follicular morphology of the ovary, an elevated ratio of LH/FSH, and often obesity and/or insulin resistance. PCOS also represents a state of chronic low-grade inflammation that is closely interlinked with the metabolic features. Inflammatory processes consist of the acute inflammatory response and resolution processes initiated concomitantly. "Classical" pro-inflammatory lipid mediators like prostaglandins (PG), leukotrienes (LT), or thromboxanes (TX) are derived from arachidonic acid (AA) and are crucial for the initial response. Resolution processes are driven by four families of so-called specialized pro-resolving mediators (SPMs): resolvins, maresins, lipoxins, and protectins. SPM biosynthesis starts from the essential polyunsaturated fatty acids DHA, DPA, or EPA via certain hydroxylated intermediates (18-HEPE, 17-HDHA, 14-HDHA). The present study aimed to establish lipid mediator profiles of PCOS patients compared to healthy women to identify differences in their resolutive and pro-inflammatory lipid parameters. Material and Methods: Blood samples were taken (20 ml), separated into plasma and serum, and analyzed by HPLC/MS-QQQ. Fifteen female patients (18-45 years) were diagnosed with PCOS according to Rotterdam criteria, and five healthy women, as comparator group, were recruited for the study. The main outcome measures were: Pro-inflammatory lipid mediators (PG, LT, TX) and their precursor AA; SPMs (Resolvins, Maresins, Protectins, Lipoxins), their precursors EPA, DHA, DPA, and their active biosynthesis pathway intermediates (18-HEPE, 17-HDHA, 14-HDHA). Ratio [(sum of pro-inflammatory molecules)/sum of SPMs]. Results: The level of pro-inflammatory parameters in serum was significantly higher in PCOS-affected women. The ratio [(sum of pro-inflammatory molecules) / (sum of SPMs plus hydroxylated intermediates)] reflecting the inflammatory state was significantly lower in the group of healthy women. Conclusion: There is a strong pro-inflammatory state in PCOS patients. Further research will clarify whether supplementation with SPMs or their precursors may improve this state.

Keywords

PCOS; obesity; inflammation; specialized pro-resolving mediators (SPMs)

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.